Get started
ServiceNow Is Our Top Tech Compounder PickIn a tech world often driven by hype and speculation, ServiceNow NYSE:NOW stands out as a reliable growth engine—a true compounder. Unlike flashier tech names, ServiceNow delivers steady revenue growth and expanding margins, all while offering mission-critical software to businesses. 📈 What’s a Compounder, Anyway? Compounders are companies that grow steadily over time by reinvesting profits at high returns. They may not make headlines, but they consistently outperform by: - Growing demand for their shares - Reducing share supply (or keeping dilution low) These are the businesses long-term investors love: predictable, resilient, and scalable. 🧩 Why ServiceNow Fits the Bill ServiceNow has quietly built a powerful B2B software business, helping organizations streamline operations. Here’s why it qualifies as a compounder: Strong Revenue Growth: From $3.3B in 2020 to $11.4B today Rapid Profit Growth: Net income jumped from $34M to $1.54B in the same period Operating Leverage: Margins have grown from 3.4% to 13.2%, thanks to stable 80%+ gross margins and low incremental costs Recurring subscription revenue is rising fast—up 20% YoY—driven by the mission-critical nature of its software and increasing AI capabilities. 💸 The Valuation Case Although many quant models give NOW a weak grade for valuation, context matters. Historically, the stock is trading in the middle of its typical range—about 18x sales and 58x free cash flow. Looking ahead: Analysts forecast 20% annual EPS growth through 2027 That implies a forward P/E of 42x, with potential to drop further as margins expand Combine that with AI-powered upselling and potential share buybacks, and NOW’s valuation starts to look compelling. ⚠️ Risks to Watch Premium Price Tag: If markets decline, richly valued stocks like NOW could fall harder Tough Competition: Rivals like Salesforce and Palantir are aggressively chasing similar markets ✅ Bottom Line ServiceNow may not be flashy, but its financial performance, recurring revenue model, and growth runway make it a solid long-term bet. If management reins in share dilution and continues margin expansion, this stock could deliver serious compounding over the next decade. Rating: Buy
NYSE:NOWLong
by PropNotes
COIN long -- currently in Wave 3 of 5 wave advance I've been using Elliott Wave Theory to look at COIN's price action. We seem to be in the middle of Wave 3. - Wave 1: April 7, 2025 to May 22, 2025 - Wave 2: May 23, 2025 to June 13, 2025 - we pulled back right below the 23.6% Fibonacci retracement level with ~$244 serving as support. - Wave 3: June 14, 2025 - now. The third wave usually has 5 distinct sub-waves. As of July 7, 2025 We appear to be in the 3rd sub-wave of wave 3. Using the upper channel line, price target for this wave is around $408-$410. Quite possible if we see BTC move up explosively, which also seems imminent given the highest weekly close on July 6, 2025. COIN is a very volatile stock that has explosive moves to the up and downside. I think we still have more room to run in this current wave 3--even beyond sub-wave 1 peak at $380.
NASDAQ:COINLong
by KGOF
5
DDOG: Navigating Key Support and Resistance ZonesAscending Trendline/Channel: o A prominent green ascending trendline, starting from the lows in April, defines the current bullish momentum. o This trendline has acted as dynamic support, with the price bouncing off it on multiple occasions. As long as the price remains above this line, the intermediate-term uptrend is considered intact. Key Support Zones (Green Bands): o Primary Support (130 to 135): This is the most immediate and critical support zone. Historically, this area acted as resistance in late 2024 and early 2025. Now, it is being tested as potential support—a classic example of a "role reversal" or "polarity" principle. The price is currently trading just above this zone. o Secondary Support (118 to 120): If the primary support at 130-135 fails to hold, the next significant level of support is identified between 118 and 120. This zone provided support in the latter part of 2024. Key Resistance / Target Zones (Red Bands): o 1st Target / Resistance (~155): This level represents the first major overhead resistance. The chart shows a recent sharp rejection from this area, which initiated the current downward move. For the uptrend to continue, bulls would need to break and hold above this zone. o 2nd Target / Resistance (~165): Should the price overcome the 155 level, the next major resistance is identified around 165. This corresponds to the major high seen at the end of 2024. Current Price Action: DDOG recently tested the resistance near 155 and has since pulled back. The price is now situated at a crucial juncture, hovering above the primary support zone of 130-135 and approaching the main ascending trendline. Summary of Observations: The confluence of the horizontal support zone (130-135) and the ascending trendline creates a significant area of interest. • A hold and bounce from this confluence could signal a continuation of the uptrend, with the 155 and 165 levels as the next potential upside objectives. • A decisive break below both the 130 level and the ascending trendline could signal a shift in momentum and may lead to a deeper correction, with the 118-120 zone as the next major support to watch. Disclaimer: The information provided in this chart is for educational and informational purposes only and should not be considered as investment advice. Trading and investing involve substantial risk and are not suitable for every investor. You should carefully consider your financial situation and consult with a financial advisor before making any investment decisions. The creator of this chart does not guarantee any specific outcome or profit and is not responsible for any losses incurred as a result of using this information. Past performance is not indicative of future results. Use this information at your own risk. This chart has been created for my own improvement in Trading and Investment Analysis. Please do your own analysis before any investments.  
NASDAQ:DDOGLong
by ManiMarkets
ORACLE Can you foresee it at $2000??Oracle (ORCL) is having perhaps the most dominant recovery from Trump's Tariff lows out of the high cap stocks, trading comfortable on new All Time Highs. This is no surprise to us, as like we've mentioned countless times on our channel, we are currently at the start of the A.I. Bubble and heavy tech giants are expected to see massive gains until 2032, where we've calculated the end of this Bull Cycle and the start of a strong Bear. As mentioned, this situation is extremely similar to the Dotcom Bubble of the 1990s. Of course Oracle is nearly impossible to repeat the +38637% gains of that Golden Decade after the 1990 Oil Crisis but in Fibonacci price and time terms, it can technically complete a +3411% rise and hit $2000 in the next 7 years. If you have a long-term investor mindset like us, this is a must stock to buy and hold. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:ORCLLong
by TradingShot
Tesla (TSLA) Market UpdateTesla NASDAQ:TSLA shares dropped nearly 7% after Elon Musk dismissed analyst Dan Ives' suggestion to scale back his political activities. Musk also proposed a new pay package, raising concerns among investors about potential distractions from Tesla’s core business. 📊 Upcoming Catalyst: Tesla is set to report its Q2 earnings on July 23, with investors eagerly awaiting updates on the company’s financial performance and the newly launched robo-taxi service in Austin, Texas. ⚠️ Sentiment: Recent bearish headlines include: Concerns over potential Robotaxi issues The ongoing Trump/Elon Musk political drama 📈 Trading Opportunity (Long Setup): Despite the negative sentiment, this dip could offer a solid long entry opportunity: Entry Zone: $275–$270 Take Profit Targets: TP1: $315 TP2: $335 Stop Loss: Close below $265
NASDAQ:TSLALong
by Richtv_official
1
Bark | BARK | Long at $0.84BARK, Inc. NYSE:BARK is a dog-focused company offering subscription-based products like BarkBox and Super Chewer, delivering monthly toys, treats, and pet supplies. It operates in Direct-to-Consumer and Commerce segments, selling through its website, retail partners, and e-commerce platforms. While not overly bullish here, especially given the economic / recession-fear headwinds, I think this is one of those stocks that may have a future "pop" as interest rates are lowered, or news emerges of the company expanding to new retail partners. A few insiders have recently purchased shares (~$75k under $1.00) and others have been awarded options. The book value currently rests near $0.64. It may dip between that price at $0.50 in the near-term. However, that's just been the trajectory of SO many of these SPAC stocks... dip then pop or bust. Fundamentally, nothing to uproar over and this is a risky investment (Nasdaq delisting may occur). The positive is the debt-to-equity in 0.9x, which is pretty good for a small company. But 2026 is expected to be its worst earnings year. The future may look bright in 2027 and beyond, but can the company last? Time will tell. Thus, for a swing trade, NYSE:BARK is in a personal buy zone at $0.84 with a risk of further near-term decline between $0.50 and $0.64. Targets into 2027 $0.95 (+13.1%) $1.25 (+48.8%)
NYSE:BARKLong
by WorthlessViews
Hasboro | HAS | Long at $66.00Hasboro $NASDAQ:HAS. Bouncing in an out of the historical simple moving average (SMA). While it may take a bit for it to spring out and continue its upward trend, it looks poised to do so. However, there is a small price gap that was never closed in the $40's that investors should stay cautious of if the downward trend continues. But a "confirmation" of a reversal will be either a continued move up or a retest of the lower historical SMA band (to close the recent price gaps) followed by a further move up. Fundamentally, NASDAQ:HAS has a high level of debt, but earnings growth is forecasted in its future. At $66.00, $ NASDAQ:HAS is in a personal buy zone, but patient investors may wish to wait for further confirmation of a reversal. Target #1 = $73.00 Target #2 = $81.00 Target #3 = $87.00 Target #4 = $119.00 (very long-term...)
NASDAQ:HASLong
by WorthlessViews
1
Figs Inc | FIGS | Long at $5.24Figs Inc $NYSE:FIGS. Technical analysis play first, fundamentals second. My selected historical simple moving average lines have converged with the stock price, which often leads to sideways trading and a reversal in the downward trend (i.e. future price increase). The downward trend is flattening, but that doesn't mean post-earnings drop to $1.50-$2.00 isn't out of the question... The FIGS brand is growing within the healthcare world with significant opportunities overseas. While economic headwinds may impede near/medium-term growth, revenue is anticipated to grow into 2027. EPS is expected to rise from 0.01 in 2024 to 0.20 by 2027. While this is not a "value" play and there is high risk for rug pulls, something may be brewing within the chart for a move up. Tread lightly, however... Targets $6.00 $6.40 $7.00 $8.00
NYSE:FIGSLong
by WorthlessViews
Applied Materials | AMAT | Long at $169.75Republican Ashley Moody recently dropped $200k-$500k on Applied Materials $NASDAQ:AMAT. The semiconductor boom may not be over... Price-to-earnings: 21.68x (great in comparison to others...) Debt-to-equity: 0.34x (low) Cash flow: $10.4 billion (FY2024) Insiders awarded options recently Unless NASDAQ:NVDA brings the market down, NASDAQ:AMAT is in a personal buy zone at $169.75. While the price may dip in the near-term to the $140s, bullish until the semi boom dies... Targets: $195.00 $215.00 $240.00
NASDAQ:AMATLong
by WorthlessViews
Mereo BioPharma (MREO) long speculationMereo BioPharma (MREO) is a biotechnology company with a very small market capitalization – currently below 500 million USD. The company has no revenues and is fully dependent on a single key project: a clinical trial for a treatment of osteogenesis imperfecta (commonly known as brittle bone disease). It is currently in Phase III of the clinical trial (ORBIT), with final results expected by the end of 2025. The project is partnered with U.S.-based Ultragenyx, which is responsible for the commercialization of the therapy. According to recent data, the company has sufficient cash to operate at least through 2027. MREO stock plunged more than 30% in a single day after the company announced it is entering the final analysis phase of the study – a move the market interpreted as a risk signal. The significant price gap downward highlights how sensitive the stock is to uncertainty in clinical development. Despite this, analysts still see substantial long-term upside. JPMorgan has a price target of $7 (Overweight), BTIG sees $6 (Buy), and Needham recently lowered its target from $7 to $5 (Buy). The average target is around $7.50, suggesting a potential upside of +100% to +230% from the current price near $2.90. That said, this is a highly speculative investment. The company’s tiny market cap brings high volatility. With only one promising molecule in its pipeline, any failure in clinical results could lead to a significant drop in valuation. But if successful, the stock could rise dramatically. Disclaimer: This content is provided for informational and educational purposes only. It does not constitute investment advice or a recommendation to buy or sell securities. Investing in biotechnology companies carries high risk and may result in partial or total capital loss. Always make investment decisions independently or consult with a licensed financial advisor.
NASDAQ:MREOLong
by rencus30